Xenetic Biosciences (XBIO) Cash from Financing Activities (2012 - 2020)

Xenetic Biosciences (XBIO) has 8 years of Cash from Financing Activities data on file, last reported at $5.4 million in Q4 2020.

• Quarterly Cash from Financing Activities rose 452135.42% year-over-year to $5.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2022 was $5.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $4.0 million, changed N/A from the prior year.
• Cash from Financing Activities rose to $5.4 million in Q4 2020, from $1200.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $13.4 million in Q3 2019 to a low of -$5423.0 in Q2 2016.
• A 4-year average of $3.6 million and a median of $2.1 million in 2018 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2016 — Cash from Financing Activities plunged 105.42% — and 2020, when it surged 452135.42%.
• Tracing XBIO's Cash from Financing Activities over 4 years: stood at $8.5 million in 2016, then tumbled by 82.51% to $1.5 million in 2018, then plunged by 99.92% to $1200.0 in 2019, then surged by 452135.42% to $5.4 million in 2020.
• The last three Cash from Financing Activities figures came in at $5.4 million (Q4 2020), $1200.0 (Q4 2019), and $13.4 million (Q3 2019), per Business Quant data.